COVID-19 outcomes in MS

  1. Erica Parrotta
  2. Ilya Kister
  3. Leigh Charvet
  4. Carrie Sammarco
  5. Valerie Saha
  6. Robert Erik Charlson
  7. Jonathan Howard
  8. Josef Maxwell Gutman
  9. Malcolm Gottesman
  10. Nada Abou-Fayssal
  11. Robyn Wolintz
  12. Marshall Keilson
  13. Cristina Fernandez-Carbonell
  14. Lauren B. Krupp
  15. Lana Zhovtis Ryerson

Reviewed by

Read the full article

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1212/nxi.0000000000000835
  2. ScreenIT

    SciScore for 10.1101/2020.05.12.20094508: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board StatementIRB: NYU School of Medicine Institutional Review Board approval was obtained for the study.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variablenot detected.

    Table 2: Resources

    No key resources detected.

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    Our study has several limitations. This was a convenience sample and not randomly selected, nor was the entire practice systematically surveyed. Patients were identified during routine teleneurology visits, if they notified the office, or if hospitalized. This likely led to an over-representation of more symptomatic individuals. Although we used a systematic questionnaire to collect relevant data, we could not verify this data independently unless the patient was seen by NYU Langone-affiliated physician or hospital. Compounding this problem was lack of access to COVID-19 testing in our area. Less than half of our patients (48.7%) underwent SARS-COV2 PCR testing. As shown in Table 4, subgroup analysis showed that this group was not different from the overall sample with respect to demographic or MS-related features. Our early experience with COVID-19 at NYU Langone MSCCC could inform clinicians taking care of MS patients during the pandemic. Our findings suggest that individuals with MS who experience COVID-19 have similar disease course, outcomes, and risk factors for complications as the general population. Rigorous, population-based studies are needed to confirm our preliminary findings and better define the risk of COVID-19 infection with respect to individual DMTs.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2020.05.12.20094508v1 on medRxiv